Biotech
Commented by Nico Popp on September 25th, 2026 | 07:50 CEST
Breakthroughs in Skin Cancer Treatment: New Approaches from Biofrontera and Moderna – Vidac Pharma Faces a Busy Fall
For a long time, the treatment of skin cancer and its precancerous stages resembled a makeshift compromise: Doctors used scalpels, froze affected areas, or prescribed aggressive creams that destroyed tissue. It was not uncommon for patients to suffer pain and weeks of delayed wound healing. But a completely new dynamic is currently emerging in the sector. Suddenly, innovations involving light beams, messenger RNA (mRNA), and the metabolic reprogramming of cancer cells are making headlines. We present the latest developments in skin cancer and its precancerous stages. The race for innovation has only just begun.
Read
Commented by Stefan Bode on September 25th, 2026 | 07:45 CEST
Breakthroughs, Production Launches and Billion-Dollar Contracts – Almonty Industries, Secunet Security Networks, Viking Therapeutics
Strong clinical trial data, the launch of a strategically important raw-materials production facility, and a potential billion-dollar contract are driving market activity. The three companies presented today could benefit from long-term megatrends such as obesity therapies, secure supply chains, and rising defense spending. However, high growth opportunities are offset by clinical risks, operational challenges, and ambitious valuations.
Read
Commented by Fabian Lorenz on September 22nd, 2026 | 07:45 CEST
Analysts See Multibagger Potential: Nordex, Evotec and Aspermont
Analysts see multibagger potential in Aspermont's stock. The Australian company appears to be making good progress in its transformation from a specialist publisher into a scalable provider of data and analytics for the global resources industry. The stock has yet to take off. Its 2028 P/E ratio is below 10. Nordex is no longer a bargain. Analysts see further growth opportunities, but the stock has already priced in much of that potential. Nevertheless, analysts recommend buying the shares. The US business is becoming increasingly important. Buying Evotec shares is not an obvious choice right now. The stock has fallen below EUR 3, while positive company news is being ignored by the market. Could this perhaps be an opportunity?
Read
Commented by Matthias Schomber on September 22nd, 2026 | 07:25 CEST
Puma at Rock Bottom, Novo Nordisk Riding the Weight-Loss Boom and Volatus Aerospace in Rebound Mode: Who Is the High-Flyer?
Broadly speaking, the stock market in Germany, as well as across Europe and globally, is currently under considerable pressure. Two wars in Iran and Ukraine, along with discontent in Germany with the current government, are weighing on markets. In other words, the stock market is under significant strain. The major indices are at or near critical technical levels. Puma, for example, is struggling with margins, while analyst price-target cuts and an upcoming change in the company's head of sales are adding pressure. Novo Nordisk, meanwhile, is facing regulatory headwinds and increasing competition in the US despite rapidly growing future markets in the obesity segment. Volatus Aerospace, by contrast, is raising hopes of a rebound with new government contracts for tactical reconnaissance drones. A technical breakout could make the stock an interesting candidate for strong performance. Read on to learn why Puma still requires plenty of patience, which billion-dollar investments are supporting Novo Nordisk's pipeline, and how investors could potentially take advantage of an entry opportunity in Volatus now.
Read
Commented by Fabian Lorenz on September 21st, 2026 | 07:45 CEST
Following Stock-Market Legend André Kostolany: Are Siemens Energy, BioNTech or HPQ Silicon Contrarian Plays?
Contrarian investors, take note! The stock market does not always behave rationally. Stock-market legend André Kostolany liked to compare the relationship between a company's performance and its share price to a man out for a walk with his dog. Sometimes the dog runs ahead, sometimes it lags behind, but ultimately both move in the same direction. HPQ Silicon appears to be a case in point. While the company has been releasing one positive announcement after another, its stock has come under pressure. This discrepancy is precisely what makes the stock interesting for contrarian investors. Siemens Energy presents almost the opposite picture. The stock has already priced in a great deal of growth, while analysts are recommending a "Sell". And what about BioNTech?
Read
Commented by Armin Schulz on September 21st, 2026 | 07:30 CEST
Novo Nordisk, BioNxt Solutions, Evotec: When Injections Become Pills, The Cash Starts Rolling In
The daily injection has had its day. For a long time, taking biologics in pill form was considered a pipe dream, but as of this year, it is becoming a billion-dollar business. On September 17, 2026, Novo Nordisk announced a partnership with Orbis Medicines worth up to USD 1.4 billion to make injections available orally. In February, the Danish company secured a partnership with Vivtex worth up to USD 2.1 billion. Whoever can deliver peptides through the stomach could see the industry come knocking. We are taking a closer look at Novo Nordisk, BioNxt Solutions and Evotec, which cover the entire spectrum of this trend—from acquisitions to technology to development.
Read
Commented by Matthias Schomber on September 17th, 2026 | 07:20 CEST
Jungheinrich, BioNTech and Almonty Industries: The Hidden Comeback Opportunities for Your Portfolio
The market environment is currently rather weak, characterized by slightly falling share prices across the stock markets. In the commodities markets, however, especially in oil, prices are rising slightly to more sharply, by contrast. Investors are getting increasingly nervous, a trend also reflected in bond yields. Yet it is precisely in such phases, when nervousness takes over and many market participants throw in the towel, that attractive entry opportunities can emerge for savvy investors. That is why today we are looking at three very different companies that nevertheless have one thing in common: they could be heading for a rebound or an upward move. With BioNTech, we look at a company focused on the oncology sector. Jungheinrich takes us into the world of warehouse logistics and mechanical engineering — a genuine industry veteran. Finally, we turn to Almonty. The company was once a hidden gem in the commodities sector. That is no longer the case, however: given its strategic importance to the Western defence industry, it has become increasingly difficult to overlook. Join us on an analytical journey through financial statements and charts to discover where interesting opportunities may arise in terms of risk and return.
Read
Commented by Nico Popp on September 16th, 2026 | 06:55 CEST
The End of Weight-Loss Shots? Innovations at Merck and Novo Nordisk—BioNxt Solutions Poised for a Hot Fall?
The battle against excess weight is no longer merely a lifestyle issue. Medical professionals now view extreme obesity as a chronic disease that weakens the body and can lead to serious cardiovascular conditions, as cardiological studies have shown. By contrast, sustained weight loss can help pave the way to a longer, healthier life. This insight, combined with pharmaceutical innovation, has sparked an unprecedented race to develop weight-loss drugs. Companies are searching for the ideal way to boost metabolism while making medication as easy and convenient to take as possible.
Read
Commented by Jens Castner on September 16th, 2026 | 06:50 CEST
Tungsten, Beer and Vaccines: What Almonty Industries, Heineken and BioNTech Have in Common
A commodities company whose share price has tripled in a single year because an unassuming heavy metal has become a sought-after, scarce commodity. A brewing giant that has been operating a cash cow in Africa for decades and has a clear strategy for increasing margins. A pharmaceutical pioneer writing its next chapter after the end of the COVID boom—with a factory that literally consists of shipping containers. At first glance, Almonty Industries, Heineken and BioNTech do not have much in common. But upon closer inspection, all three are betting on the same underrated market. Here is how you, as an investor, can benefit.
Read
Commented by Carsten Mainitz on September 15th, 2026 | 10:30 CEST
New Approaches to Fighting Cancer: Why Vidac Pharma, BioNTech and Evotec Deserve Attention
Cancer cells use sophisticated defence mechanisms to evade the immune system and reprogram their own metabolism. These mechanisms are now increasingly being targeted by biotech companies. BioNTech has more than EUR 16 billion in cash and is driving the next generation of immunotherapies. Evotec is scaling up drug development through strong alliances but has eroded investor confidence. This skepticism is weighing on its share price. Developments at Vidac Pharma are particularly exciting. The company focuses on the metabolic reprogramming of malignant cells. Results from a potentially groundbreaking Phase 2b trial are imminent. Which approach offers the greatest promise?
Read